Hyderabad-based vaccine maker Indian Immunologicals (IIL) on Wednesday started work on a Rs 75 crore viral antigen manufacturing facility in Genome Valley, Telangana that will enhance its viral vaccine making capacity by 35 per cent by October 2021.
The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation. The new viral antigen facility will be specially designed as a multi-product facility.
IIL also inaugurated a sterile filling facility today that has come up with an investment of Rs 75 crore.
K Anand Kumar, Managing Director of IIL said “We are optimistic about the strategic investment as India is one of the key growth markets.” He added that the new facility will boost IIL’s manufacturing capacity 35 per cent and the new plant is expected to be completed by October 2021.
It will be a Biosafety level-2 and 3-compliant plant. Biosafety level-3 plants are appropriate for work involving microbes, which could cause serious and potentially lethal diseases, through the inhalation route. Plants are categorised according to the level of safety to handle disease causing pathogens.
The company also plans to utilise the cutting-edge facility to manufacture Covid-19 vaccines post completion of its R&D with Griffith University, Australia.
As for the sterile filling facility, it will increase IIL’s capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) Abhayrab.
As a part of the expansion plan, IIL will add over 150 new positions, bringing its total staff strength close to 1,500.
IIL has four manufacturing facilities at various locations: Karkapatla, Telangana for human vaccines & animal health formulations; Ooty, Tamil Nadu for anti rabies; Hyderabad, Telangana for human biologicals (Gachibowli) and animal vaccines; Dargaville, New Zealand (New Bovine Serum(. IIL exports various Human and animal vaccines to over 50 countries.
The company is one of the largest producers of foot-and-mouth disease vaccine in the world and was the first in India to launch the purified Vero cell rabies vaccine for humans (PVRV) and second globally.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU